Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3075 of 3499 entries
View as:

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Phase: N/A Priority: Normal
NCT ID: NCT00843882 Org: User:
Start: 01/29/09 End: 10/02/25 Due: 10/02/26

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06015880 Org: User:
Start: 05/20/24 End: 06/29/26 Due: 06/29/27

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05538897 Org: User:
Start: 03/31/23 End: 01/31/27 Due: 01/31/28

Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05669664 Org: User:
Start: 07/20/23 End: 04/11/27 Due: 04/11/28

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04802174 Org: User:
Start: 06/01/21 End: 12/01/27 Due: 12/01/28

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03811002 Org: User:
Start: 07/26/19 End: 02/21/26 Due: 02/21/27

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT06954987 Org: User:
Start: 09/18/25 End: 05/15/28 Due: 05/15/29

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT01189240 Org: User:
Start: 12/31/10 End: 02/28/15 Due: 02/28/16

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06589804 Org: User:
Start: 03/27/25 End: 11/30/29 Due: 11/30/30

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

Phase: N/A Priority: Normal
NCT ID: NCT02196181 Org: User:
Start: 09/19/14 End: 03/15/26 Due: 03/15/27

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Phase: N/A Priority: Normal
NCT ID: NCT06228066 Org: User:
Start: 06/13/24 End: 09/01/28 Due: 09/01/29

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01886573 Org: User:
Start: 06/30/13 End: 02/28/15 Due: 02/28/16

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Phase: N/A Priority: Normal
NCT ID: NCT00112671 Org: User:
Start: 04/30/05 End: 05/31/10 Due: 05/31/11

Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families

Phase: N/A Priority: Normal
NCT ID: NCT00341627 Org: User:
Start: 02/01/99 End: 07/06/20 Due: 07/06/21

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Phase: N/A Priority: Normal
NCT ID: NCT00590785 Org: User:
Start: 08/13/96 End: 01/13/15 Due: 01/13/16

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00486642 Org: User:
Start: 09/30/07 End: 09/30/15 Due: 09/30/16

BMS-247550 in Treating Patients With Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00036764 Org: User:
Start: 02/28/02 End: - Due: -

Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR

Phase: N/A Priority: Normal
NCT ID: NCT00001698 Org: User:
Start: 06/30/98 End: 06/30/04 Due: 06/30/05

Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00064324 Org: User:
Start: 06/30/03 End: - Due: -

Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01421862 Org: User:
Start: 09/30/11 End: - Due: -

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01247571 Org: User:
Start: 01/31/11 End: 01/31/16 Due: 01/31/17

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02659943 Org: User:
Start: 01/21/16 End: 12/31/22 Due: 12/31/23

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

Phase: N/A Priority: Normal
NCT ID: NCT01341496 Org: User:
Start: 04/18/11 End: 07/21/16 Due: 07/21/17

Precision-Based Genomics in Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04706663 Org: User:
Start: 09/14/21 End: 06/30/27 Due: 06/30/28

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00079144 Org: User:
Start: 01/31/04 End: 08/31/05 Due: 08/31/06